Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings-Reference-Cited by-同舟云学术

Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings

Published:2021-07 Issue: Volume: Page:
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Blauvelt Andrew,Shi Nianwen,Somani Najwa,Burge Russel,Zhu Baojin,Ridenour Terri L.,Lew Carolyn R.,Zimmerman Nicole M.,Atiya Bilal,Murage Mwangi J.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Dermatology

Reference14 articles.

1. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review;Kamata;Int J Mol Sci,2020

2. Old and new biological therapies for psoriasis;Rønholt;Int J Mol Sci,2017

3. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17;Grine;Cytokine Growth Factor Rev,2015

4. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis;Krueger;J Allergy Clin Immunol,2012

5. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3);Papp;Br J Dermatol,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence to Psoriasis Therapies;Dermatologic Clinics;2024-07

2. Biologics protect psoriasis patients from being exacerbated by COVID-19 infection;Heliyon;2024-01

3. Reporting, handling, and interpretation of time‐varying drug treatments in observational studies using routinely collected healthcare data;Journal of Evidence-Based Medicine;2023-12

4. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium;Immunotherapy;2023-10

5. Biomarkers and biologics related with psoriasis and psoriatic arthritis;International Immunopharmacology;2023-09